OoDJsigTr Ersvelopa ID.. 305A8W&4D4-8AE44122.F680CIPAE87A
Registered number: 11943477
Charlty numbei: 1185091
FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)
AUDITED TRUSTEES. REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
*AFBKF6sr*
2PJ09r2026
CCWPAWIES HOUSE
A18
#57

Dor#JstyJn EnveloFe10.. 30&48&4&8AD4-&4E4-8122.F680C1A8EB7A
FOLUCULAR LYMPHOMA FOUNDATION
(A company limited by guarantee
CONTENTS
Page
Reforence and administrative d•tails of the Company. ils Trustees and advI￿r$
Trustees. report
2-13
Independent audltorfs repwt on the financlal statements
14-17
Statement of financial activities
Balance sheet
19
Statement of cash flows
20
Not•s to th• financlal statements

DcrJJsigTr Envelope10.. 30sA65￿&4D4-8AE4￿l22￿8BDC1A8E87A
FOLLICULAR LYMPHOMA FOUNDATION
{A company Ilmlted by guarantee)
REFERENCE AND ADMINISTRAnVE O￿AlLs OF THE COMPANY. ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 31 DECEM8ER 2025
Trnstees
Lady N S Menddsohn. Chair
Lord J N Mendelsohn
Lord R l Harrington
P M V Thompson
A Wong
J J Burley
Dr J W Simons
Company register•d
number
11943477
Charity registered
number
1185091
Regislored office
417 Finchley Roaj
London
NW3 6HJ
Chlef executlve officer
E France (appointed 1st Feb￿￿ry 20251
Independent auditor
Cooper Parry Group Limited
Cubo Bimiingham
4th Fkx)r
Two Chambertain Square
Birmingham
B3 3AX

Doojsign Énvaope ID.. 305A65AWW4-8122.FWC1A8E87A
Folllcu .
FOLUCULAR LYMPHOMA FOUNDATION
TRUSTEES. REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
The Trustees, who are also the directors of the charity for Ihe purposes of the Companies Act
2006. present their report together the financial statements for the year ended 31
Decernber 2025. The financial stalemenls have been prepared in accordance with the
Charities SORP (Statement of Recommended Practice). applicable to charities preparing their
accounts in accordan￿ with the Financial Reporting Stsndard applicable in the UK and
Republic of Ireland (FRS 102). effeclive 01 January 2019.
Objectives and Activities
Our mission is to help those with follicular lymphoma. a currently incurable blood cancer. to
live well and get well by finding and funding the best research to identify breakthroughs that
will change how we understand and Ireat the condition. We provide follicular lymphoma-
focused information resources for patients and work to ensure palients, voices are at the heart
of the search for better treatrnents and a cure.
More s
ecrficall the Chari
's ob"eclives are the followin
A. To sponsor basic and translational ￿Search to assist in the development of better
treatments and a cure for follicular lymphoma induding sponsoring the establishment of
an international challenge to scienttfic and Clinical researchets to focus on prospective
cures.
To support the promotion of the "patient Vol￿.. by supporting patient advocacy and
education. the development of patient communtiies and evaluating the efficacy of
patient-reported outcomes on current treatments and side effects to assist clinicians
and pats'ents.
C. To improve health outcomes by way of stimulating research and evaluation of
complementsry condttions to supplement medical treatment.
Publlc Benefit - The Trustees confirm that they have complied with their duty to have due
regard to the Charity Comrnission's public benefit guidance when reviewing the charity's
objectives, activities and future plans. The Trustees consider that the charity's activities provide
public benefil by funding research into follicular lymphoma, supporting the development of
better treatments and approaches to care, providing trusted infomiation and support for people
affeded by follicular tymphoma. and ensuring pats'ent experTrence helps shape research,
education and engagement priorities.
Achievements and perfomiance
2025 was a year of focused progress for the Follicular Lymphoma Foundation (FLF). Scientrfic
understanding advanced. new treatrnent approaches moved closer to patients. and
expectations of what is possible continued to shtft. FLF tumed urgency into practical
mornentum by funding research thal targets the biggest barriers to cure. engaging patients at
scale and building the partnerships needed to move promising science further and faster.
The Follicular Lymphoma Foundatron
fo@Iheflf.019
ww.thelll.Or¥
+441012034178563
FR
FUINDgAISINIG
REGULATOR

Docustgn Envebpelo.. 30SA85￿eAO￿Ed-8122-F6BDC1ME87A
FOIII¢v
hof
In 2025, FLF invested in cure-focused research and patient programmes. supported artive
translational research programmes addressing relapse, treatment resistance and treatment
durabilily, captured patient experience through global survey responses and wider
ommunity engagernent. and direded the majority of expenditure toward research and
patient programmes.
Tt)Jether, this shows a clear model in which donor support enables research, research
creates pathways to palient benefiL and patient insight ensures progress is anchored in
what matters most in real life.
When I look at what has been achieved in 2025. 1 feel a powerful mix of pride and
determination. Pride, because the progress is real. Detennination, because il is not yet
enough. Every study. every data point and every collaborafyon is a step toward the future
patients deserve.. one where follicular lymphoma is no longer a lrfe-defining diagnosis. Cure
cannot wait. Neither carp we."
Nicola Mendelsohn CBE. Founder and Chair.
Follicular Lymphoma Foundation
2.1. Research programrnes
The FLF'S research programmes are designed to tum promising science into better patient
outcomes for people affected by follicular lymphoma. Each programme addresses an
important unmet need, with the potential to improve treatment and move closer to cure. At the
heart of every programme is a clear-so Wha￿.: what this could thange for patients. what new
evidence it could generate for the field. and how FLF'S support helps improve Pat￿nt
outcomes sooner.
2.1.1. The CURE FL Awards
The CURE FL (Curative Research to Eliminate Follicular Lymphoma) Awards were the first
round of FLF'S CURE FL Programme. designed to answer one of ihe bKJgest questions in
follicular lymphoma." why does the disease return after powerful immune-based treatments,
and how can we stop it? This programme ran from De￿rnber 2022 to July 2025 in
collaboration with the Milken Institute. deploying approximately $2 million across four
translalional research projects. Each project received $500.000 over IAVO years. The focus was
on transfomiative projects addressing relapse and treatment resIStsn￿ after immunoiherapy.
area5 FLF identified as having the greatest potential to generale eviden￿ that could lead lo
better therapies rea¢hing patients sooner.
What it made possible
The CURE FL Awards helped move promising scientific discoveries closer to the people who
need them most. Across four Iranslational research projects, the programme generated new
insights into treatment ￿Sistance and relapse after immunotherapy, strengthened
understanding of the biological mechanisms that drive relapse, and helped advance promising
discoveries from the laboratory towards patient studies. The programme also generated
evidence. collaborations and new scientific insights that exterm4 beyond follicular lymphoma.
helping infom) research across the wider lymphoma field.
The Follicular Lymphoma Foundalion
Infr@Ihefll.Or9
wvrw.theflf ov9
+4410120341Y8SB3
FR
FUiNiDR&ISING
REGULATOR

Docusvjn ETrvdope ID.. 305485￿0At)4&1£&al22￿68Oc1A8EB7A
Folll¢u .
What we learned
The CURE FL Awards showed that relapse after immunotherapy is not an immovablè barrier.
The funded projects generated new insights into immune escape. treatmenl resistance and
how treatment responses could become deeper and more durable. Two projects progressed
to the final preclinical stages required before potential testing in patients. with one of these
going on to inform two clinical studies. A third projecl mel its objectives by validating a potential
new strategy to prevent relapse and generating the eviden￿ needed to move that approach
closer to patients. The fourth generated useful insights that continue to infomi the field, and
FLF will Continue lo monitor future developments arising from this work.
Why it matters
Collectively, these outcomes demonstrate how translational research Can "advance
understanding. infomi future studies and help bring cure doser for people living with follicular
lymphoma. By answering critical questions about why treatment stops working and what drives
relapse, the programme is helping identrfy new approaches that could lead to more durable
responses and improved outcomes for people living with FL. The knowledge generated may
also help infom research into related blood cancErs that share similar biological pathways.
Read more
2.1.2. Research Unlted to CURE FL Awards
Building on the first CURE FL Awards. Research United to CURE FL is the second round of
FLF'S CURE FL Programme. Launched in 2024 in partnership with Blood Cancer United,
formerly the Leukaemia & Lymphoma Society, and the Inslitute for Follicular Lymphoma
Innovalion, the partners awarded $2.25 million to three promising follicular lymphoma
research projects.
What il focuses on
Research United to CURE FL supports translational research designed to move scientific
ideas closer to clinical trials and patient benefit. The funded projects focus on three areas with
clear relevance to patients- understanding resistanc8 to immune-based treatments,
developing more We￿Se targeted therapies. and testing a chemotherapy-free firsl-line
treatment approach.
Why it matters
As Ireatment options grow. the challenge is not only finding new therapies but knowing how
to use them better. Patienls need treatment approaches that are more precise. less toxic, and
more likely to deliver deep, lasling responses. The biological queslions these projects address
are also relevant beyond follicular lymphoma. with the potential to inform research into related
blood cancers.
2025 progress
In 2025, the Research United to CURE FL projects advanced novel targeted therapies,
completed enrolment to a 35-patsent chemotherapy-free clinical trial with encouraging early
results. and generaled new biological samples. data and research models to better understand
why follicular lymphoma can persist or retum after treatment. Togelher, the projects delivered
their first planned outputs and generated findings that will infomi the next phase of research.
Read more
The Follicular Lymphoma Foundation
if*f￿he 1lf.org
444{0120 3417 8583
FR
FUNDR.4ISING
REGULATOR

Dc¢)Jsgn Envebpe10.. 305A85A&8AD4-&AE44122.F6BDC1P4E87A
Folllcu .
2.1.3. Tho FL Biomarker Discovery Programm•
Launched in 2024 with projects activated in March 2025, FLF partnered with The Mark
Foundation for Cancer Research on the FL Biomarker Discovery Programme. This partnership
supports research to identify biological markers that could help predicl how follicular
lymphoma behaves and how patients may respond to treatment. Over time, biomarkers could
help support new treatment approaches and potentially preventative strategies. The
programrne was developed with scientific. clinical and patient input. It focuses on key moments
in higher-risk disease. including transformation, eady relapse and the early biological changes
that can lead to follicular lymphoma.
What It focuses on
A biomarker is a biological signal, such as a molecule. protein. or gene. that can help predict
what is happening in Ihe body and what may happen next. Reliable biomarkers for follicular
lymphoma do not currently exist. This programme supports research using advanced
technologies to better understand follicular lymphoma tumours. the irnmune cells around
them, and the patterns that may be linked to relapse. transformatTron. or treatment response.
Why it matters
Biomarkers could mean clearer answers at moments of uncertainty.. who may need treatment
straight away. who may be at hNJher risk of relapse or transformation. and which treatmenl
approach may be most appropriate. For patients and clinicians. this could support more
personalised decisions, reduce unnecessary treatment and
enable earlier action when needed.
2025 progress
In 2025, the ￿ selected projects were awarded, supporting research at The University of
Texas MD Anderson Cancer Center and Yale School of Medicine. The two-year funded
projects use advanced spatial technologies to study follicular lymphoma tumours and their
surrounding immune environmenl. Tcoether, they aim to identify pattems that could predict
prognosis, progression, transformation. and response to treatment.
Read more
2.1.4. PETReA Plus Programme
PETReA Plus is a UK-based observational study generating critical data from people no￿￿Y
diagnosed with follicular lymphoma. Led by Professor Kim Linton al The Universiiy of
Manchester. the programme runs from Seplember 2024 to September 2029 and is funded in
partnership with Blood Cancer UK and The joy￿ and Nomian Freed Charitable Trust. The
sludy is designed to help clinicians and patients make more informed. personalised decisions
about treatment in the future. It is contributing to what is expected to become one of the largest
global resources of follicular lymphoma data and patient samples. creating a resource that
could support future research well beyond this individual study.
What It focuses on
PETReA Plus is collecting outcomes from the initial management of people newly diagnosed
with follicular lymphoma. It sits alongside PETReA, an intemational trial focused on
understanding the best use of rituximab according to dsfferent risk groups.
The Follicular Lymphoma Foundalion
info@Ihe 111.org
WWw.Ihellf.or9
+44101203417 8583
FR
FUIIDWISINIG
REGULAfoR

OrLus¢gn Envtbpe ID.. 305A8SA&8A￿44122-F6B￿1I4E87A
Foiiicu
hof
Why It matters
As treatment options grow. one of the most important questions is how to use them well.
PETReA Plus will help address knowledge gaps that cannot be answered through current
clinical Irials alone. By capturing evidence from routine care, the study could help link different
diagnoses and treatment approaches with different outcome5. SUPPOrting more personalised
care. better-informed decisions and fewer unnecessary toxic trealments.
2025 progress
With a target of r8cruiling 500 patients from 65 sites in the UK, the PETReA Plus study team
made consistent progress in 2025 towards preparing for rewitment. By December 2025. the
first patient had been recruited to the study.
"The real detenninant of whether a study sinks or swims is how popular it is with local sites -
how many sites want.to nin the study and how enthusi8Stic they are about recniiting patients.
I see the whole spectrum across my area of clinical research, and I have to say this on8 IS
flying, now the sites are starting lo open."
Dr An(ty Pettttt. co-investigator on the PETReA
Plus study
Read more
2.2. People affected by folllcular lymphoma at the heart of our work
The FLF supports people today while leaming from lived experience to shape tomom)w.
People affected by follicular lymphoma help inform the charity's research. patient information
and future programmes through suNeys. discussion sessions and patient representatives,
ensuring the work remains grounded in the outcomes that matter most in real life.
2.2.1. Patient support and education
Living with follicular lymphoma raises questions about diagnosis. trealment. uncertainty and
where lo find reliable support. FLF provides accessible, expert-informed informalion based on
up-t&date evidence. along wth opportunities to hear from experts and others affected by the
disease.
In 2025, 14.438 people used Your Su
ort Hub on the FLF website for trusted infomiation and
support. 22.765 webinar views connecled patients and caregivers with expert insight and lived
experience, and 123,000 views of patient stortes helped peoplè feel less alone and more
informed.
This support has immediate practs'cal value.. people are better equipped to understand follicular
tymphoma, prepare for conversats'ons with their healthcare teams and make informed
decisions about their care. It also helps people feel less alone and more connected to a
community that understands what they are facing. Over time. better infomation also supports
the FLF'S wider mission. When people understand research, dinical studies and the role of
patient participation. they are better placed to engage with opportunities that can help develop
new treatments and move the field doser to cure.
"I very much appreciate everything that this team puts together to keep your global audience
and patients 'in the kno￿ and w811 infonn8d. I think you do an absolutely amazing job on such
a large scale." Anonymous restK)nse to the FLF patient survey
The Follicular Lymphoma Foundation
nlo@thelll.org
v4ww.theiif.org
+441012034178583
FR
FUINDPA￿S1NG
REGULATOR

Docusign Envekye ID.. 3O5A85A8.8AD444E4-8l22￿6BDCl￿Ee7A
Folllcu
2.2.2. The patient voice
People affected by follicular lymphoma help shape FLF'S research. patient infomation and
future programmes through surveys. discussion sessions and patient representatives. Patient
insight ensures FLF focjjses not only on what is scientifically possible. but also on the
outcomes thal matter most to people Irving with follicular lymphoma, from reducing uncertainty
and improving communication to supporting informed treatment decisions.
In 2025, patient insight helped inform research strategy, global patient suNey content and
interpretation, scientific education for healthcare professionals. and events and parlnerships
focused on improving patient outcomes. This brings FLF doser to cure by grounding scientific
priorities in real patient experience, so research focuses on what could make the greatest
difference in people's lives.
35 highly engaged palient contributors helped shape FLF'S research and patient information,
1,042 responses were received through FLF'S global patient survey, and more than 100
countries were represented through community engagement and wider networks.
An example af patient insight in action
Through the Global Patient SuNey and focus groups in 2025, people affected by follicular
lymphoma helped shape FLF'S global patient survey through a face-to-face workshop.
Through further online discussions. they also played a key role in interpreting the findings.
Their insight highlighled the real-life importance of treatment preferences, uncertainty,
communication and decision-making about dinical tn'als.
The difference it made.. these insights were shared directly with researchers and healthcare
professionals at forums such as the American Society of Haematology symposium and FLF
investigator workshops. helping ensure research and care are shaped by patiènt priorities.
By bringing the patient voice into global decision-making. this work supports more meaningfvl
sha￿d decision-making and.helps patients access the treatments that are rbght for them.
.1 was actually quite anxious prior to the meeting but quickly felt it so worthwhile. Hearing the
views of others living with FL and being heard was importanl. The opportunity to help is huge."
Lived Experien￿ Discussion Attendee
2.3. Mobilising funding and partnorshlps
Cure for follicular lyrnphoma will not come frcyn one individual. one organisation, one discipline
or one type of eXpe￿'Se acting alone.
FLF brings together researchers, dinicians, data specialists. industry partners, philanthropic
funders and people living with follicular lymphoma around shared priorities, so that funding,
expertise and patient ins￿ht can work harder together. This helps ensure the mosl promising
science reaches people faster and moves follicular lymphoma closer to cure.
"Pn?gress depends" on collaboration. No single organisation can move the f￿ld alone, but
logelher we can proted momentum. align effort and keep patients at the centre.. Emma
France, Global CEO. The FLF
The Follicular Lymphoma Foundation
inlo@the ri1.￿9
W¥yw.thellf.org
444101203417 8583
FR
FUNDRAISING
REGULATOR

Do¢usign Ér*v¢l¢¥e ￿.. 3o&A8YA4AD¥￿4-8l22468Oc}ABEB7A
Folllcu .
2.3.1. What partnership made posslble in 2025
Larger, more ambitious research programmes
Strategic partnerships enabled FLF to pool expertise and funding around larger. more
ambitious research programmes. including Research United to CURE FL. the FL Biomarker
Discovery Programme and PETReA Plus.
A stronger bridge across fields
FLF connected expertise from lymphoma research. immunology, clinical care. drug
developfflent. philanthropy and patient experience, so promising work was shaped by more
than one field from the start.
Trusted patient education and Inslght
FLF delivered palient education. preference research. webinars and healthcare professional
engagemen( keeping patient need at the centre.
A shared case for collal)oration
FLF co-authored an article wth the Institute for Follicular Lymphoma Innovation and Blood
Cancer Unf(ed on the Importan￿ of collat*)ration in accelerating prog￿SS for people living
with follicular lymphorna.
2.3.2. Key global partners In 2025 included:
The Mark Foundation for Cancer Research - SuprM)rting h￿h-lrnpact cancer research that
aC￿lerateS breakthroughs in how cancer is understocrfl and treated. Co-funded the FL
Biomarker Discovery Programme.
Mllken Institute Center for Strategic Philanthropy COllat￿rating with the FLF to
Strengthen strategic philanthropy. accelerate research and advanc8 patient-focused
innovation.
The Institute for Follicular Lymphoma Innovation - Advancing research and innovation lo
support the devdopment of more targeted therapies for follicular lymphoma.
Blood Cancer United - Working wtth the FLF to fund innovative follicukir lymphoma research
through the Research United to CURE FL Awards and other shared initiatives.
Bl¢)od Cancer UK - Partnering with the FLF to deepen understsnding of follicular lymphoma
and support progress toward more tailored therapies.
DKMS Supporting the FLF'S cure-focused research into new treatment approaches and
technologies that could help improve outcomes for people living with folliGular lymphoma.
Patlenl Group Partnerships - Working closely wtth global online communities that provide
safe spaces, shared experience and SUPF)Ort for thousands of people affeded by follicular
lymphoma. This includes the Livin
wtlh FL FacebcM)k
rou
and Linfoma folicular= Comunidad
Internacional de Pacientes
Familiares
The Follicular Lymphoma Foundation
1nloéllhelll.ors
www.thÈlll.Or9
•441012034178583
FR
FUINDQ.4151NG
REGULATOR

Oocu8ign Enveknpe ID.. 305A85A8-8AD4-8AE4-8122.F6BDClhSE87A
Folllcu
hor
Working across the wider field
Alongside our ￿Search and funding partnerships. the FLF works with clinicians, industry
partners, healthcare educators and scientific communities where there is clear alignment wilh
our mission and direct value for pats"ents. The FLF'S independence remains ￿ntral. We work
with partners to strengthen patient voice, improve understanding and suppcrt better outcomes.
while keeping patient need and cure-focused progress at the centre.
Plans for future periods
2025 showed what focused funding. patient insight and scientific collaboration can make
possible. while reinforcing the challenge ahead= as research advances. progress must stay
focused on the oulcomes that matter most lo people living with follicular lymphoma.
In the next phase, FLF is focused on tuming this progress into stronger evidence. better-
infomied decisions, deeper patient involvement. more aligned funding, clearer pathways from
discovery to patient benefit, and insights that can inform research beyond follicular lymphoma.
What we are focused ¢)n next
Moving cure-focused Scien￿ closer to patients.
Building on our CURE FL portfolio to support
research to understand what drives follicular
lymphoma, identify people at greater risk, tackle
relapse and treatment resistance. and improve
treatmenl a
roaches.
Accelerating the development of new treatment
approaches. Collaborating with partners to
advance precision medicine-guided dinical
trials and accelerate approval of innovatNe
treatments for relapsed follicular lymphoma.
What
ress looks like
Stronger evidence. clearer nexl steps
and, where appropriate. the potential to
inform future clinical studies.
Approval and availability of treatments
with breakthrough designation (wh8n
regulators
recognise
potential
to
significantly improve palient outcomes)
for relapsed follicular lymphoma. bringing
newo
tions to
atients sooner.
Better tools and evidence to support
more infomied treatment decision5.
reduce unnecessary treatment and side
effects, and improve outcomes for
different groups of patients.
Making
treatment
more
personalized.
Advanang biomarker research, PETReA Plus
and other dat&driven work lo better understand
who may need treatment, when, which
treatment may be most appropriate and how
care can be better tailored to each
erson.
Ensuring patient insight shapes what comes
next. Using surveys, discussion sessions.
patient meet-ups and patient contn"butors to
understand what matters most in real life.
including treatment preferences. uncertainty,
communication and clinical trial decisions.
Building partnerships that accelerate progress.
Working with researchers. clinicians. nonprofrt
organizations. funders. industy partners and
patient communities lo pool resources, share
ex
ertise and reduce du
lication.
Research
priorities,
educational
resou￿$, partnerships and measures of
success that continue to be clearly
grounded in the needs and experiences
of people living Wlth follicular lymphoma.
More aligned funding. shared learning
and faster movement from scienlific
discovery toward patient benefit.
Together, these areas will guide FLF'S continued work to lum promising science into better
answers, better treatment decisions. longer-lasting responses and, ultimately. cure, while
generating knowledge that can benefit research far beyond follicular lymphoma.
The Follicular Lymphoma Foundation
inlo@thpfll.ory
WW*.ihefif.or9
*441012034178583
FR
FUllD￿ls1NG
RÉGULATOR

Do¢uggn Envelo￿ 10. 3ow5A&8A￿44l22.F6BDC1￿Ee7A
Folllcu .
Financial Review
4.1. Financial Position
The financial stalemenls for the year ended 31 December 2025 show a surplus of £47.078.
This positive result reflects the ojnts'nued support of our donors and partners, together with
prudent financial management throughout the year.
The charity remains in a strong financial position, providing a solid foundation from whith to
expand its activities and further advance its charitable objectives in the years ahead.
4,2. Reserves Policy
As of 31 December 2025. th8 charitys totsl funds and reseNes amounted to £1.286,694.
The charity operates with a lean cost structure and rArefully manages its resources to
maximise the funds available for charttable activities.
The Trustees have established a reserves policy designed to ensure the charity maintains
sufficient financial stability to manage operational risks and meet its ongoing commitments.
The Trustees have determined that free reseprfes should be maintained at a level equivalent
to approximately Ihree mnths of planned expenditure. This level is considered appropriate in
light of the charity's operating model. committed expenditure. fundraising profile and ability to
fflanage costs and commitments through regular forecasting and Board oversighl.
The Trustees will continue to monitor free reserves throughout the year against the approved
budget and forecast cash requirements. In addition to maintaining the formal reserves policy.
the Trustees will seek to strengthen the charity's broader financia! resilien￿ over tirne by
diverstying income, managing expenditure carefully and building the funds available lo
support fulure growth and long-term sustainabilily.
4.3. Going Concem
The Trustees have assessed the chariws financial position. fulure plans and cash flow
forecasts and are satisfied Ihat bt remains appropriale lo prepare the financial ststements on a
going concern bas1S.
This assessment is supported by an approved business plan and budget covering thè period
to De￿rnber 2027. The charity undertakes regular financial planning and fflonitoring. including
the preparation of updated forecasts throughout the year. enabling expenditure and resource
requirements to be reviewed in detail while maintsining a long-term strategic focus.
The Trustees continue to explore opportunities to strengthen the charity's long-term financial
sustsinability and diversify income streams. This supports the fomial reserves policy by
increasing financial flexibility and resilience. while ensuring that resources ￿maIn available to
deliver the charity's approved plans and charitable objectives.
The charty has also o)ntinued to strengthen its organisattonal structure and operational
capacity, demonstrating its commitinent to delivering its charitable objectives over the long
tem.
Having considered the charity's financial resources. forecast income and expenditure, and
future plans, the Trustees have a reasonable expectation that the charity has adequale
resources to continue operaling fof the foreseeable future. Accordingly, they Gonsider the
going concem basis of accounting to be appropriate in preparing these financial statements.
The Follicular Lymphoma Foundation
inlo@thelll.org
WYiw.Ihellf.oig
+441012034178583
FR
FUINDRAISING
REGULATOR

Docusign Envelopa ID.. 305A85A8-8ADMAE44122-F6Btt1A8E87A
hof
4.4. Prfnclpal Risks and Uncertalntles
The Trustees are responsible for idents'fying, assessing and managing the principal risks facing
the charity and for ensuring that appropriate systems and controls are in place. During Ihe
year, the Trustees reviewed the charity's risk profile, with particular focus on the risks most
relevant to FLF'S scale. intemational activities. research funding model and reliance on donor
support.
The principal risks considered by the Trustees include: income volatilty and concentration
risk. given the importance of major donors and philanthropic partnerships- research delivery
risk. including the need to ensure grants are awarded. monitored and evaluated effectively,.
regulatory and Cornplian￿ risk across the charity's UK and international operating context:
data protection and infomation governance risk. particularly where patient engagement,
surveys and digilal communications are involved- people and capacity risk as the organisation
grows- and reputational risk arising from the charity's public profile, partnerships and patient-
facing adivities.
These risks are managed through Board oversight. regular financial reporting and forecasting,
grant govemance and milestone review, due diligence on partners and funded activities,
appropriate policies and procedures. data protedion controls. Insuran￿ cover and ongoing
review of organisational capacity- The Trustees also seek extemal professional advice where
required, including in relation to legal. regulatory. employment and financial matters.
The Trustees are satisfied that appropriate policies. procedures and c¢￿trOlS are in place to
reduce the charity's principal risks to an acceptable level and to provide reasonable assurance
against fraud, error and non-compliance. As FLF'S activities, partnerships and international
reach Continue lo develop. the Trustees will keep the risk management framework under
review and strengthen it where needed.
4.5. Structure, governance and management
The Follicular Lymphoma Foundation {"FLF") is a charilabl8 company, incorporat8d in England
and Wales and registered with both the Charity Commission for England and Wales and
Companies House.
The charitable company was incorporated on 12 April 2019 and is govemed by its
Memorandum and Articles of Association. wh￿h set out Ihe charity's objects, powers and
govemance arrangements.
FLF was registered as a charity with the Charity Commission on 29 August 2019. The
Trustees, who are also the directors of the charitable company for the purposes of company
law, are responsible for the overall governance and strategic direction of the charity and for
ensuring Ihat it pursues its charitable objectives in accordance with its governing documents
and applicable legislation.
The Follicular Lymphoma Foundation operates through three separate legal entities, each
estsblished arKI regulated within its respective jurisdiction..
The Follicular Lymphoma Foundation {FLF UK)
a charitable company
incorporated in England and Wales and registered with Ihe Charity Commission for
England and Wales and Companies House.
The Follicular Lymphoma Foundation US Inc. (FLF US) - a regislered 501{cl(3)
charitable organisation in the United Statss with Employer Identification Number {EIN>
84-2338899.
The Follicular Lymphoma Foundat40n
iDI￿the111.0rg
www_thplTI.Org
+441012034178583
A*wkt*rèdwith
FR
FJINDQAISING
REGULATOR

DO￿$￿)n Enwdope ID.. 30W5A8-8AD44AE48122-F68DC1A8E87A
Folllcu .
ho(
The Follicular Lymphoma Foundation (FLF) Israel Ltd. {FLF Israel)
an Israeli
registered charity recognised under Section 46 of the Israeli Income Tax Ordinance.
with company registration number 516798477.
Each organisation is a separate legal entty with its own goveming board, statutory obligations
and independent audit. While legally distinct. the three charities operate in close collaboration
to deliver the Foundation's global mission. Many research. fundraising and operational
programmes are undertaken joinlly across the entities to maximise impact and ensure
coordinated delivery.
FLF UK provides central operational and administrative support to FLF US and FLF Israel,
including finance, govemance and other shared servI￿s. The costs of these services are
recharged to the respective entities in accordance with agreed arrangements and are subject
to approval by each entity's Board of Directors or Trustees, as appropriate.
4.5.1. Decision Making
The Board of Truste8s meets fomially at least four times each year and is responsible for
setting the strategic diredion of the charty, establishing key policies, and overseeing the
effective delivery of its charitable objectives.
The Trustees monitor the charitrfs performance. financial position. risk management
framework and the impact of r(s activities, ensuring that resources are used effectively and in
furtherance of the charity's mission.
The Board comprises individuals with a diverse range of professional skills, expertise and
experience relevant to the tharity's a¢b'vities. including govemance. finance. fundraising.
research. healthcare. business and communications. This breadth of knowledge supports
robust decision-making and effective oversight of the tharity's operations and long-term
development.
4.5.2. Statement of Trustees. Responslbilities
The Trustees {who are also the directors of the Follicular Lymphoma Foundation for the
purposes of company law) are responsible for preparing the Rep)ort of the Trustees and the
financial statements in accordance with applicable law and United Kingdom Accounting
Standards (United Kingdom Generally AC￿pIed Accounting Practice) including Financial
Reporting Standard 102"The Financial Reporting Standard applicable in the UK and Republic
of Ireland.
Company law requires the Trustees to prèpare financial statements for each financial year
which give a true and fair view of the state of affairs of the charitable company and of the
incoming resources and application of resources. including the income and expenditure, of the
charitable company for that period.
In preparing those financial statements. the Trustees are required to:
select suitable accounting pdicies and then appty them consistently
observe the fflethods and principles in the Charity SORP
make judgements and estimales that are reasonable and prudent
state whether applicable accounting standards have been followed, subject to any
malerial departures disdosed and explained in the financial ststements
prepare the financial ststements on a going concem basis unless it is inappropriate to
presume that the charitable company will continue in business
The Follicular Lymphoma Foundation
info@iheflf.019
ww.thefll.org
+44 IOIZ034178583
FR
FUINDPAISING
REGULATOR

D[￿S19Th Envekye ID.. 3o5A85A8￿-8AE4-8I22.F680cIlIEa7A
hor
The Trustees are responsible for keeping proper accounting records which disclose with
reasonable accuracy at any time the financial posib'on of the charitable company and to enable
them to ensure thal the financial statements comply with the Companies Act 2006. They are
also responsible for safeguarding the assets of the charitable company and hence for taking
reasonable steps for the prevention and deleclion of fraud and other irregularities.
So far as the Trustees are aware: there is no relevant audit information of which the charitable
company s auditors are unawara" and
the Trustees have taken all steps that they ought to have taken to make themselves
aware of any relevant audit information and to establish that the auditors are aware of
that infomation.
Auditors
The auditors. Cooper Parry Group Limited, NMII be proposed for re-appointment at the
forthcoming Annual General Meeling.
Report of the Trustees. incorporating a strategic report, approved by order of the board of
Trus188s, as the company directors. on 25 September 2026 and signed on the board's behalf
by:
by:
DAfj2894W78..:................
Lord J N Mendelsohn - Trust8e
The Folli¢ular Lymphoma Foundation
info@Iheflf.ov9
www.thefll.ory
44410120 34178583
FR
FUiqDRAISINIG
REGULATOR

Docu5vJn ErweI0￿ ID". WwSA&8A￿uI22-F6BDelABE87A
FOLLICULAR LYMPHOMA FOUNDATION
(A company limiled by guarantee}
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF FOLLICULAR LYMPHOMA FOUNDATION
Oplnlon
We have audited the financial slalements of Follicular Lymphoma Foundation (the 'charitable compan1} for the
year ended 31 December 2025 which comprise the Statement of finanual activf(ies. the Balance sheet. the
Slalement of cash flows and the related notes. including a summary of significant accounting policies. The
financial retx)rb'ng framework that has been applied in their preparat￿￿ is applicable law and United Kingdom
Accounting Sland8rds. ￿ClUdIng Financial Rep)rting Slandard 102 The Financial Reporting Standard
applicable in the UK and Republie of Ireland. (United ￿.￿gdoM Generally Accepted Accounting Practice).
In our opinion the financial stalements:
give a true and fair view of the state of the eharrtable companys affairs as at 31 December 2025 and of
ils incoming resources and application of resources. including ils income and expenditure for the year
then ended"
have been properfy prepared in accordance with United lQngdom Generally Accepted Accounllng
Practice-. and
have been prepared in accordance wtth the requireffEnts of the Charities Act 2011.
Basis for opinion
We conduded our audit in aCCordar￿e with Intemational StsrKlards on Audtting (UK} (ISA5 IUK)) and applicable
law. Our respgnsibilities undef those standards are further described in the Audrtorfs responsibiltties for the audit
of the financial 51alemenis section of our report. We are independent of the charitable company in accordance
with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom.
including the Financi81 Reporting Counul's Ethical Standard. and we have fulfilled our other ethical
responsibilities in accordance with these requirements. We believe Ihat the audit evidence we have obtained is
sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial ststements. we have concluded that the Trustees. use of ￿ going concern ba$1$ of
accounting in the preparati￿ of Ihe financk81 statements is appropriate.
Based on the work we have perfomied. we have not identified any material uncertainties ￿Lating to events or
conditions that. individualty or colleclivdy, may cast signfficant doubt on the Charitable companys ability to
continue as a going concem for a period of at least fvRlve months from when the financial statements are
authorised for issue.
Our TesFonsibilrties and the resp￿￿bilitieS of the Truslees ￿th respect to going ec￿cern are described in the
relevant sections of this reporL
a4A

OooJ8igTr Envelop¢10". 305A85A8.8AD44AE4-8122-F68DC1NAE87A
FOLLICULAR LYMPHOMA FOUNDATION
(A company Ilmlted by guarantee)
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF FOLLICULAR LYMPHOMA FOUNDATION
(CONTINUED)
Other informatlon
The other information comprises th8 information induded in the Annual report other than the financial
statements and our Auditorfs report thereon. The Trustees are responsible for the other information contained
within the Annual report. Our opinion on the financial statements does not cover the other information and.
except lo the extent olheThMse expl10￿Y staled in our rewrt. we do not express any fomi of assurance
condusion thereon. Our responsibility is to read the other infomatyon and, in doing so. consider whether the
other infomiation is materially inconsislenl with the financial stalements or our knowledge obtained in the course
of the audit. or otherwise appears to be materially misstated. If we identify such material inconsistencies or
apparent fflatellal rnisslatements. we are required to delemiine whether this gives rise to a material
misslatemenl in the financial statements themselves. If. based on the work we have perfomied, we conclude
Ihal there is a material misstslement of this other infomiabon, we are required to report that fact.
We have nothing to report in this regard.
Matters on whlch we are requlred to report by excepllon
We have nothing lo report in respect of the following matters thre the Charities (Accounts and Reports)
Regulations 21)08 requires us to report lo rf. in our opinion:
the infom)alion given in the Tnjstees. rewrt is in￿nSIStenI in any malerial respect with the financial
slaternenls: or
sufficient accounting records have not been kept.. Of
the finanual stslements are not in agreemenl wilh the accounting records and returns.. or
we have not received all the information and explanations we require for our audil.
Responslbllltles of trustees
As explained more fully in the Trustees. responsibilities statement. Ihe Trustees {who are also the directors of
the charitable company for the purposes of company lawl are responsible for the preparation of the financial
statements and for being satisfied that they gNe a true and fair view, and for such internal control as the
Trustees delemiine is necessary lo enab￿ Ihe preparation of financial ststements that are free from material
misstatement, whether due lo fraud or error.
In preparing the financial statements. the Trustees are responsible for assessing the chafitable CoMpan￿S
ability lo continue as a going concem. disclosing. as applicable. matters related lo going concem and using the
going concem basis of accounting unless the Trustees either intend to liquidate the charitsble company or to
cease operations. or have no realistic alternative but to do so.
nts14

D￿$19￿ Envelope10.. 3QS485AmAo￿E¥6l22.F680cl￿E87A
FOLUCULAR LYMPHOMA FOUNDATION
IA company limited by guarantee)
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF FOLLICULAR LYMPHOMA FOUNDATION
(CONTINUED)
Auditorfs responslbilities for the audll of Ihe Ilnanclal statements
We have been appointed as auditor under sectTron 145 of the Charities Act 2011 and report in accordance with
the Act and relevant regulations made or having effecl thereunder.
Our objectives are to obtain reasonable assuranee atojl whether the financial statements as a whole are free
from material misslalement. whether due to fraud or error. and to issue an Auditorts report that includes our
opinion. Reasonable assurance is a high level of assurance. but is not a guarantee that an audit conducted ir¢
accordance with ISAS (UK) wll always detect a material rnisslatement when it exists. Misstatements can.anse
from fraud or error and are considered material rf. indmdually or in the aggregate, they could reasonably be
expected lo influence Ihe economic decisions of users laken on the basis of these financial 5tstements.
Irregularities. including fraud. are instances of non-compliance with laws and regulations. We design
procedures in line wth our responsibilitses. oulined above, to detect material misstatements in respect of
irregularities. including fraud. The extent to which our prowlures are capable of delecling irregularities,
induding fraud is detailed below:
Our assessment focussed on key laws and regulations the charttable company has lo comply with and areas of
the financial statements we assessed as being rnore susceptible to misstatement. These key laws and
regulations included bul were not limited lo compliance with Ihe Companies Act 2006. Charities Acl 2011.
Trustees Act 2000, Charities {Protection arKI Srxial Inveslment) Act 2016. taxation legislation, data proteelion
and employment legislation.
We are nol responsible for preverbting irregularities. including fra￿J. Our approach to delecling irregularities.
including fraud. included. but was not limited to. the following=
obtaining an understanding of the legal and regulatory framework applieable to the charitable company and
how the chaiilable ccmnpany is complwng with that framework. induding agreement ol financial statement
disclosures to underfying documenlation and other eviden￿..
obtaining an understanding of the eharitsble companls control environmenl and l￿W Ihe eh8rilable
company has applied relevant control procedures. through discussions ￿￿th Trustees and other
management and by perfoming walkthrough lesb.ng over key areas:
obtsining an understanding of the charitsble companls risk assessment process, including the risk of
fraud..
reviewng meeting minutes of those charged with govemance throughout the year, and
perfomiing audit tesling lo address the risk of management override of controls. including testing joumal
entries and other adjuslments for appropriateness. evaluating the business rationale of significant
transactions oulside the normal course of business and reviewng accounting estimates for bias.
Because of the inherent limttalirms of an audit. there ts a risk that we ￿11 not detect all irregularities, Including
those leading lo a material misstaterr£nt in the financial stslements or non-compliance wth regulation. This risk
increases the more thal compliance with a law or ￿ulatiOn is removed from the events and transacts.ons
reflected in the financial stalefflents. as we ￿11 be less like5y to become aware of instances of non-eompliance.
The risk is also greater regarding irregularit￿S occurring due lo fraud rather than error. as fraud involves
intentional coneealmenl. foigery. collu&on. omission or misrepresentation.
A further description of our resFonsibilities for the audit of the finanrial statements is located on the Financial
Reporting Coun￿1.S website at: www.frc.o
-uklauditorsre5
nsibilitses. Thi5 description forms part of our
Auditorfs report.
•1R

D(xxJ$ign Env¢kty)o ID.. 305A85￿AD4-8AE44l22￿O8tCl￿E87A
FOLUCULAR LYMPHOPAA FOUNDATION
(A company lirnited by guarantee)
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF FOLUCULAR LYMPHOPAA FOUNDATION
(CONTINUED)
Use of our report
This reKM)rt is made solely to the charilable CompanYs members. as a bcKly. in accordance with Part 4 of the
Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might stale
lo the charitable Companys members those matters we are required 10 Stale to them in an Auditorfs report and
for no other purpose. To the fullest extent permitted by law. we do not accept or assume responsibility lo
anyone other than the charitable Company and its members. as a body, for our audr( woth, for this report, or for
the opinions we have fomed.
Nichola Hodge
for and on behalf of
Cooper Parry Group Limited
Cubo Birmingham
4th Floor
Two Chambertain Square
Birmingham
83 3AX
4D52
enior
ory Auditor
25 September 2026
CcK)per Parry Group Limited are digible to act as audtlors in terms of section 1212 of the Companies Act 2006.

DocusvJn Envdepe ID.. 305￿$￿84D￿a4E￿8122.F6BDC1A8E87A
FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)
STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 DECEMBER 2025
Restricted Unrestri¢led
funds
funds
2025
2025
Totsl
funds
2025
Totsl
funds
2024
Note
Income from:
Oonalions and legacies
Investments
Other incoff
958.784
1.451.472
5.776
89.212
2.410.256
5.776
89.212
2.384,538
7,241
Total income
958.784
1.546.460
2.505.244
2,391.779
Expendlture on:
Raising funds
Charitable activities=
Research and patient programmes
Research and patient programme
support costs
250,928
250,928
224,630
870.849
1.114.792
1.985.641
2,041.408
221,597
221,597
150,479
Total expenditure
870.849
1.587.317
2,458.166
2.416.517
Net in¢omel{expenditure)
Transfers between funds
87.935
40.276
140.857)
140.276)
47.078
{24.738}
15
Net movement In funds
128.211
181.133)
47,078
124,738)
Reconciliation of funds:
Total funds brought for%Yard
Nel movement in funds
137.074
128.211
1.102.542
181,133)
1.239.616
47,078
1,264,354
124.738}
Total funds carried forward
265.285
1.021.409
1,286.694
1.239,616
Conllnuing oporations
All income and expenditure has arisen from c￿tinUing activities.

Docusvjn Envek)pe ID.. 305A85A&8A04.8AE4-8122*6Btf1￿E87A
FOLLICULAR LYMPHOMA FOUNDATION
(A company Ilrnited by guarantee)
REGISTERED NUMBER: 119434TI
BALANCE SHEET
AS AT 31 DECEMBER 2025
2025
2024
Note
Flxed assets
Tangible assets
12
9.074
7.381
9.074
7,381
Current assets
Debtors
13
18
1.043.887
988.9C
212.674
1.805.674
Cash at bank and in hand
2.032.793
2.018.348
Current liabilities
Creditors.. amounts falling due within one
year
14
{755,173)
{786.1131
Net current assets
1.277.620
1,232,235
Totsl net assets
1.286,694
1.239.616
Charity funds
Restricted funds
Unrestricted fuThJs '
15
265.28S
1.021.409
137.074
1.102.542
15
Total funds
1,286.694
1,239.616
These financial statements have been prepared in aeeordance with the provisions applicable to eharitable
companies subject to the small companie5 regirne.
The financial statements were approved and authorised for issue by the Trustees atKI signed on their behalf by..
Lord J N Mendelsohn - Tnjstee
Date.. 25 September 2026

OorJJsi9n Envelopa ID.. 305A85A￿4AE4￿122-F6BDc1AeS87A
FOLLICULAR LYMPHOMA FOUNDATION
. {A company Ilmited by guarantee)
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2025
2025
2024
Cash flows from opgrating activities
Cash generated.from operations
1817.511)
515.458
Cash flows from Investing actlvltles:
Purchase of tangible fixed assets
Interest received
15.033)
5.776
14.397)
7.241
N•t cash lused in)Iprovid•d by investing activities
743
Change in ￿$h and cash gquivalents in the y•ar
Cash and cash equivalents at the beginning of the year
(816.768)
1.805.674
518.302
1.287.372
Cash and cash equivalents at the end of the year
988.906
1,805.674

DOCUS¥￿ Enveknpe ID.. 305A8sA8-8A04￿E￿e122.F6￿1￿E87A
FOLLICULAR LYMPHOMA FOUNDATION
(A company limlled by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
Accountlng pollcles
1.1 Basis of preparation of financlal staternents
Follicular Lyfflphoma Foundation is a private eompany limited by guarantee, and is a registered
charity incorporated in England and Wales under the Companies Act 2006. The charity is registered
with the Charity Commission for England and Wales {Charity No.. 11850911.
The finanual statements have been prepared in accordance with the Charities SORP IFRS 1021-
Accounting and Reporting by Chaiities= Statement of Recomrnended Practice applicable lo charities
preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK
and Republic of Ireland IFRS 1021 (effective 1 January 2019). the Financial Reporting Standard
applicable in the UK and Republic of Ireland {FRS 102} and the Companies Ad 2006. The financial
stslements have been prepared under the historical cost convention.
The financial statements are presented in GBP {£). which is the presentational currency of the
charity.
The charity meets the definition of a public benefrt entsty under FRS 102. Assets and liabilities are
inits.ally recognised at historical cost or transaction value unless otherwise slated in the relevant
accounting policy. Individual fKJures are reP￿d in whole numbers, rounded lo the nearest £1.
12 Going concern
The financial slalements have been prepared on a going concern basis. The Trustees have
reviewed and considered relevant infomiation, including the annual budget and future cash flows in
making their assessment. Based on these assessment5. and the current resources available. the
Trustees have concluded that they can continue to adopt the goin9 concem basis in preparing the
annual report and accounts.
1.3 Income
All income is recognised once the Company has entitlement to the income. it is probable that the
income will be received and the amount of income receivable be measured reliably.
Oonations are recognised when the charity is enlilled to the income. receipt is probable and the
amount can be measured reliably. Restricted donations are credited to the appropriate restricted
fund. Donations subject to conditions that have not been met al the year4nd are d8ferred until those
conditions are sabsfied. Gift Aid is rec(gnised when the related dOnat￿n is rer))gnised.
Interest reeeivable is recognised HI the Ststemenl of Finanual Aclivities on an accruals basis as it is
earned.
1A Donated goods. seTvlces and volunteers
Donated goods. SeThI￿ and facilities are recognised as income at fair value when receipt is
probable and the value can be me85ured reliably. with an equivalent amount recognised as
expenditure or as an asset as appropriate. The time given by volunteers is not recognised in the
finawal stslements.. the role of volunteers is described in Ihe Trustees. report.

Do￿Sign Envd*Jpe ID.. 30W5A&8AD44AE44122.F6BDC1A8E87A
FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
AccountSng policles Iconlinued)
1.5 Expenditure
Ex￿ndItUre is recognised once there is a legal or constructive obligalion to transfer economic
benefit to a third paty. rt is probable that a transfer of economic benefits will be requir8d in
settlement and the amount of the obligation can be measured reliably. Expenditure is classified by
actwity. The costs of each activity are made up of Ihe lolal of direct costs and shared costs.
induding support costs involved in undertaking each acb"vrty- Direct Costs attributable lo a single
actiwty are allocated directly to that acb"vity. Shared costs which contribute to more than one activity
and support costs which are not attributable to a single acb.vity are apportioned be￿een those
activities on a basis consistent with the use ol resources. Central staff costs are allocated on the
basts of b.me spent. ar￿ depreciats.on tharges all¢)caled on the portion of the assays use.
Expenditure on raisirvJ fvnds indudes all experKlI￿re incurred by the Company to raise funds for ils
charitable purp)ses and includes costs of all fundraising activities events and non-charilable trading.
Expenditure on charitsble activities 15 inojrred on direcuy undertaking the activities which further the
C0rnpan￿S objecti've$. as well as any associated sUprM￿ ￿)sts.
Costs of actNilies indude support costs and governance costs which have been allocated befv4e8n
activities on the basis set out bekm.
Support Costs
Support costs are those lunctions that assist the work of the charity bul do not direclly undertake
charitable aclivilies. Support costs indude central office functions such as finance. human
resources. information technology and general management. These c0515 have been allocated
be￿een activities on the basis of staff time spent on each activity. whieh the Trustees consider lo be
the most appropriate basis given the nature of the eosls incurred.
Governance costs
Governance costs indude costs of the preparab.on and examination of the ststulory accounts, the
costs of trustee rneelings and the cost of any legal advice on govemance matters.
1.6 Grants and r•s¢arch funding
Grants and Tesearch funding payaue in furtherance of the ¢hariWs objects are re¢ognised as
expenditure, and a corresponding liability, once there is a legal or constructive obligation committing
the charity to the payThent and the 8mount can be measured reliably. Where funding is conditional
on future performance or events wthin the chanlls control. il is recognised only as those ¢ondibons
are Ir￿1.
1.7 Taxatlon
The Company is considered to pass the iests set out in Paragraph 1 Schedule 6 of the Finance Act
2010 and therefore it rneels the definition of a charitable company for UK corporation tax purposes.
Aeeordingly. the Company is potentially exempl from tsxats'on in respect of income or capital gains
received within cale9ories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section
256 of the Taxation of Chargeable Gains Act 1992. to the extent that such income or gains ara
applied excluswdy to charitable purposes.
The charity 1$ not registered for VAT. Irreeoverable VAT is included wthin the cost of the
expenditure or asset to whith it relates.

Docusw En¥e&)pe ID.. 3Q5A85A&8AD￿&IE4-8122.F6BOClP￿E67A
FOLUCULAR LYMPHOIAA FOUNDATION
IA company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
Accounting policies (contlnued
1.8 Tan9ibl• flxed assets and depreclatlon
Tangible fixed assets are initially recognised at cost. After recognition, under the cost model.
tsngible fix9d assets are measured at cost less aC￿mUlated depreuation and any accumulated
irnpairment 105ses. Al costs incurred lo bring a tangible fixed asset inlo its intended working
condition should be included in the measurement of cost.
Dep￿ciall0n is charged so as to allocate the cost of tangible fixed assets less their residual value
over Iheir estimated usefvl lives. using the straighl-line method.
Depreciation is Fwovided on the following basis:
Computer eqvipment
33%
1.9 Currgn¢y
The functional and presentation currency of the charity is pounds sleding {£). being the currency of
the primary economic environment in vthich it operates. Transaclions 'in foreign currencies are
translated at the rate ruling at the date of the transacbon. Monetary assets and liabilities
denominated in foreign cu￿entles.al the balance sheet dale are retranslated al Ihe closing rate. All
exchange gains and losses are recognised in the Slalement of Financial Activilies in the period in
which they arise. The charity does ￿1 use f*dging instruments.
1.10 Debtors
Trade and olher debtors are recognised at the settlement amounl after any trade discount offered.
Prepayments are valued at the amounl prepaid nel of any trade discounts due.
1.11 Cash at bank and in hand
Cash al bank and in hand indudes cash and short-term highly liquid investments with a short
maturity of three months or less from the dale of acquisiknon or opening of the deposit or similar
account.
1.12 Liabilftles and provlslons
Liabilities are recognised when Ihere is an obligation at the Balance sheet dale as a result of a past
evenL it is probable that a transfer of economic benefit will be required in settlement. an(J the
am(wJnl of the settlement can be estimated reliably.
Liabilities are recconised at the amount that the Company anticipates it will pay to settle the debt or
the amcyjnt it has received as advanced payments for the goods or services il musl provide.
Provisions are measured at the best estimale of Ihe amounls required to settle the obligation. Where
the effect of the ts.rne value of money is material, the provision is based on the present value of those
amounts. discounted al the pre-tsx dI￿unt rate that refl￿1$ the risks specific to the liability. The
unwinding of the discount is recognised in the Statement of financial activities as a finance cost.
1.13 Penslons
The charTlable company operates a defined contribulion pension scheme. Contributions payable to
the charitable companls pension scheme are charged lo the Staternent of Financial Activities in the
period to which they rdate.
. ??

Do¢u8van Envelope10.. >)s485A&eA￿u1Y2.F6BDc1￿E87A
FOLLICULAR LYMPHOMA FOUNDATION
IA company Ilmlted by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
Accounting policies (continu￿)
1.14Fund accounting
General fvnds are unrestricted fvnds which are available for use al the discrotion of the Trustees in
furtheran￿ of the general objectives of the Company and which have Thjt been designated for other
purposes.
Restricted funds are funds which are to be used in accordartce wth specific restrictions imposed by
donors or which have been raised by the Company for particular purposes. The cosis of raising and
administering such funds are charged against Ihe speafic fuThJ. The aim and use of each restrided
fund is sel out in the r￿leS to the financial statements.
Investment income, gains and losses are alIc￿ted to the appropriate fund.
Critical accounting estimates and area5 of judgment
In preparing the finanual statements. Management are required lo make judgements. estimates and
assurnplions that affect the reported amounts of assets, liabilits"es, income and expenditu￿. Estimates
and underlwng assumplions are based on historical experience and other factors considered reasonable
in the circumstances. and are reviewed on an ongoing basis. Actual results may differ from these
eslirnales.
The areas involving a higher degree of judgement. or where assumptions and estimates are significant to
the financial slatemenls. are-.
ReseaTch grant and programme commitments - iudgem8nt is applied in detemiining wheth8r a legal or
constructsve obligation exists at Ihe year end. and the amounl al which any resulting liability is reeognised.
The rrK)st significant such commitment is included withtn aceruals {note 14).
Accft￿ income - judgement and estimation are applied in detemining enlitlemenl to income receivable
but not yel received at the yew end, and the amount at which it is re¢Tr3nised {nole 13}.
Critic81 aecounting estimates and assumptions"
The Company rnakes estimates and assumpknons CA)nceming the future. The resulting accounting
estimates and assumption5 will. by definitson. seldom equal the related actual results.
944D44ar_tSxS2Sf*-£5b64￿.W5Gj6**￿￿%8￿￿-￿￿￿-.cft:-.?4

Oocu51gn Erwek¥e ID.. 305A85A8-6ADmAE4-8122.F68Dc1￿E8?A
FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 202S
Income trom donallons
Restricted Unrestricted
funds
funds
2025
2025
Total
funds
2025
Donations
Donated Services
958,784
1,340.774
110.698
2.299.558
110.698
Total 2025
958.784
1,451,472
2,410,256
Donaied services principally comprise legal and communications support. These a￿ ￿cOgnised as
income al the fair value of the services received al the dale of donation. based on the estimated value to
Ihe charity, with an equivalent amount recognisedas expendilure in the year.
Restrictod Unrestricted
funds
funds
2024
2024
Total
funds
2024
Donations
960,914
1,423,624
2,384,538
Investment income
Unreslricted
funds
2025
Total
funds
2025
Deposil accounl interest
5.776
5,776
Unr•stricted
funds
2024
Total
funds
2024
Deposit account interest
7.241
7.241
l-.£*w*ixi?.::'
. ?

DooJsign Envelcpe ID.. 3Os485A&8A￿4￿l22.F6B0c1￿Es7A
FOLLICULAR LYMPHOMA FOUNDATION
{A company Ilmited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
Other Income
Unrestrlcted
funds
2025
Total
funds
2025
Total
funds
2024
Recharge of shared costs wth FLF US
89.212
89212
Expenditure on rnislng funds
Fundralslng trading expenses
Unrestricted
funds
2025
Tolal
funds
2025
Fundraising fees
Allocation of overheads
Event costs
Fundraising trading expenses- wage5 and salaries
Fundraising trading expenses - Nl
Fundraising trading expenses - pension costs
13.805
25.999
117,127
81,819
10.905
1.273
13.805
25.999
117.127
81.819
10.905
1.273
Tolal 2025
250.928
250.928
Unrestricted
fund$
2024
Total
funds
2024
Fundraising fees
Allocation of overheads
Evenl costs
FurKlraising trading expenses - wages and salaries
Fundraising trading expenses- Nl
Fundraising trading expenses- pension costs
1,431
28,912
107.893
76.104
9,678
612
1,431
28.912
107,893
76.104
9.678
612
Total 2024
224,630
224,630

Dr￿U$*jn En¥eK)pe ID." 305A85A&8AD4-8AE4-8122-F6BLK1A8E87A
FOLUCULAR LYMPHOMA FOUNDATION
(A company Ilmlted by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
Analysis of expenditure on charitable activities
Summary by fund type
Restricted Unrèstricted
funds
funds
2025
2025
Total
2025
Research and patient programmes (including wvemance
cosls}
Intercompany staff costs recharged
Research and patient programme SUPFth costs
781,637
89.212
1.114.792
1.896.429
89.212
221.597
221.597
Totsl 2025
870.849
1.336.389
2.207.238
Reslri¢ted Unrestricted
funds
funds
2024
2024
Total
2024
Research and patient programmes (including govemance
costs)
Research and patient kyogramme SUPFMNI costs
1,369,078
670,662
152,147
2,039,740
152,147
Total 2024
1.369.078
822,809
2,191.887
Analysis of expenditure by activities
Governance
Direct
rasèarch
research and patient
and patient programme
programme
support
sts
2025
Total
funds
2025
2025
Research and patient wogrammes
Intercompany staff costs recharged
Research and patient wogramme support costs
1.873.764
89.212
22.665
1.896,429
89.212
221.597
221.597
Total 2025
1,962,976
244,262
2.207.238
?7

DoDJsign Envelopg ID.. 30sA85A8-8A￿4￿122-FeBDclA8É87A
FOLLICULAR LYMPHOMA FOUNDATION
IA Company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
Analys1$ of expendlture by actlvltbes lcontinued)
Governance
Direct research and
research
patient
and patient programme
programme
support
Costs
2024
Tolal
fvnds
2024
2024
Research and patient pro9rammes
Research and patient programme support costs
2.020.780
18.960
152.147
2.039,740
152.147
Total 2024
2.020.780
171.107
2.191,887
Anatysis of support costs
Research
and patient
programrne
SllPPOrt
costs
2025
Governance
Costs
2025
Total
funds
2025
Staff costs
Marketing and Communications
IT support cosis
Travel and aeeommodation
Bank eharges
Database & CRM
132,403
50,027
25,900
1.521
2.539
21.761
1.144
77.023
3.340
1.795
29.¢4J4
1.203
167
132,403
50.027
25,900
1,521
2,539
21,761
1.144
77,023
3.340
1.795
29,004
1.203
167
Postage and stslionery
Legal expenses
Depreciation
General and other
Operating lease expenses
Event ￿$1S
Staff training
Stsff training and Recnjitsnent
Re-allocation of ovetheads to direct programmes
Foreign exchange losses
Govemanee costs
23.838
1176,8091
26.741
23,838
(176.8091
26.741
22,665
22.665
Total 2025
22,665
221,597
244,262
*l

Dc¢usign Envgw ID: 3o5A85M￿-8AE4-8l22-F6BDcIA8EB7A
FOLLICULAR LYMPHOIAA FOUNDATION
IA company Ilmlted by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
Anatysis of expebKllture by activities (continued)
Analysls of support costs Icontlnued
Research
and patient
programme
support
costs
2024
Governance
Costs
2024
Total
funds
2024
Stsff costs
Marketing and Communications
Support and consultancy
IT and support
Travel and accommodation
Bank charges
Database & CRM
Poslage and staliongry
Administrative support
Legal expenses
Depreciation
General and other
Operating lease costs
Staff training and Recruitrt*nt
Re-allocation of overheads to direct prcgrammes
Foreign exchange gain
Govemance costs
182,444
42.190
28.760
16.229
470
2.422
18.064
395
13.857
3.845
2.015
2.797
24.344
46,777
1226,265)
16,197)
182,444
42,190
28.760
16,229
470
2.422
18,064
395
13.857
3.845
2.015
2.797
24.344
46,777
{226,2651
{6,1971
18,960
18.960
Tolal 2024
18.960
152.147
171,107
Where grant agreements provide for Ihe recovery of a ￿ntribUtion towards the charitys central costs,
thal funded element is recognised within the direcl costs of the relevant charitable adivity I'cost
recovew). Central costs that are not recovered from funders are appoI￿oned across the charitys
aclivilie5 and sh¢)wn as support costs. This ensures that costs met by funders are reported against the
activity they support. while the residual cost of running the charity is transparenuy disdosed as support
cost.
Auditorfs remuneration
2025
2024
Fees payable to the Coryanys auditor for the audit of the Companrfs
annual accounts
15.000
13.500

Do￿J￿n Envdope ID.. 30S485AWD4-eAE44122.F68OC1PAE87A
FOLLICULAR LYMPHOMA FOUNDATION
(A company lirnited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 310ECEMBER 2025
10. Staff ￿$ts
2025
2024
Wages and salaries
Social security eosts
Contribution to defined contribution penS￿n schemes
680.871
92.684
7.504
612.299
74.976
6.680
781.059
693,955
The average numbgr of persi?n5 employed by the Company during the year was as follows..
2025
No.
2024
No,
Ernployees
The average headcount distinguished between full time and part time staff are as follows:
2025
No.
2024
No.
Full lime employees
Part time employees
The number of employees whose employee ￿nerts (excluding employer pension costsy exceeded
£60.000 was..
2025
No.
2024
No.
In the band £60,001 - £70,000
In the band £70.001 - £80.000
In the band £90,001 - £1M.OCwJ
In the band £220,001- £230.LK)O
In the band £240.IK)1- £250.CM)O
Key management personnel comprise the members of the Senior Management Team, being those
persons having authority and responsibility for planning, directing and controlling the activities of the
charity. The lolal employee benefits of key management personnel were £478.17912024.. £412.3101.

D¢oJ*gn Envelope ID.. 305A85A&8AD4-8AE48122.F68DC1A8E87A
FOLLICULAR LYMPHOMA FOUNDATION
{A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
11.
Trust8es' remunoration and gxp•nwJ
During the year. no Trustee5 rKeived any remuneratM)n ￿ other benefits {2024 - £Nill.
Donations from Trustees
During the period. the lotsl aggregate amount of unrestricted donations from Trustees was £82.750
(2024.. £84,000).
During the year ended 31 December 2025. no Trustee expenses have been incurred12024 - £Nill.
12.
Tangible fixed assets
Computer
equlpment
C05t or valuation
At 1 January 2025
Additions
19,661
5,033
Al 31 December 2025
24.694
Depreciation
Al 1 January 2025
Charge fof the year
12,280
3,340
Al 31 December 2025
15.620
Net book value
At 31 December 2025
9.074
Al 31 De¢ernber 2024
7,381

Qrfu$ign Emiewe ID.. 30W5A84AD4-8AE414122￿fjBDCl￿Ee7A
FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)
NOTES TO ThE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OECEMBER 2025
13. Debtors
2025
2024
Due within one year
Trade debtors
409.330
634.557
200.631
12.043
Prepayments and acc[L￿1 income
1.043.887
212,674
14.
Creditors: Amounts falling due within one year
2025
2024
Trade creditors
Other tsxation and social securrty
Olher Creditors
Accruals and deferred income
126.348
25.362
2.220
601.243
18,262
22,558
1.937
743.356
755.173
786,113
The amount of deferred income induded in accnwls and deferred income is £nil (2024: £nill.
. ?_3K3¥-:
??

DrKusNJn Envelope10.. 30SNASA&W-&4EU122.F68DC1P*E87A
FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
15. Statement of lunds
Statement of funds . current year
Balance at
Tranyfers
31
between December
funds
2025
Balance at 1
January
2025
Income Expenditure
Unr¢strith funds
Unrestn'ded funds
1,102,542
1.546.460 (1,587.3171
{40.276)
1.021.409
Balance at
31
December
2025
Balance at 1
January
2025
Transfers
between
funds
Income Expenditure
Reslrided funds
Mark Foundation for Cancer
Research- towards CURE
FL research
DKMS Stiftung Leben
Spenden
CURE FL
70.832
. 70.832
(50,532)
78.966
12.654
632.111
226.673
1621.855}
1165.894)
{12.654)
40.276
139.745
Blood Cancer UK
The Joyce & Noman Freed
Charitable Trust
25,154
1￿,(￿)0
{70,446)
54,708
137,074
958.784
1870.849)
40.276
265.285
Total of fund5
1.239.616
2.505.244 {2.458.166)
1.286.694
The Mark Foundation
The funds are lo fund one Momentum Fellow. a posldocloral researcher conducting evidence-based
laboralory, data, andlor medical science research al a non-profit institution.
DKMS Stfftung Leben SpendeTr
The funds are to fund feasibility and Phase 2a din￿al trial evaluating the safety, feasibility. and
preliminary effectiveness of huCART19IL18 therapy adfflinislered 7Mthout lymphodeplelion in patients
with relapsed or refractory fdlicular lyn)phoma.
CURE FL
This programme brings together the BIOCKI Cancer United (BCU) formerly Leukemia & Lymphoma
Society ILLS), the Fdlicular Lymphoma Foundatson {FLF), and the Institute for Follieular Lyfflphoma
Innovation IIFLII to ioinUy fund high-quality. innovalive research thal advances the treatment of fDIIiGular
-lymphoma.-
Blood Cancer UK & The Joyce & Nonnan Fr¢od Charitable Tru$t
Fundirsg lo idenlify Irealmenl pattems, dinrcal outcomes and risk clusters for newty diagnosed FL (FLI
and de novo transfomied FL {tFL) undergoing treat￿L
4A4a-?y￿Cl￿4fj=.
. 72

DocusvJTr Envelope10.. 3O5A85A&￿E44l22￿68Dc1A8EB7A
FOLLICULAR LYMPHOMA FOUNDATION
IA company lirnited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
15. Statement of fvnds lconllnuedl
Statement of funds - prior year
Balance at
Transfers
31
between December
funds
2024
Balanco at
1 January
2024
Income Expenditure
Unrestrlcted funds
Unrestricted funds
1,103.336
1.430.865 (1.047.439)
{384.220}
1.102.542
Balance at
31
Dacember
2024
Balance at
1 January
2024
Transfers
between
funds
Income Expenditure
Restricted funds
Maurice Wohl Charitable
Foundation - lowards Cure
FL research
Mark Foundati￿ for Cancer
Research - towards CURE
FL research
DKMS Stsftung Leben
Spenden
CURE FL
9).186
(173.9361
83,750
70.832
70,832
526.840
246.574
87.500
(577,3721
(468,0781
(74.8461
150.532)
78.966
12.654
300.470
Blood Cancer UK
The Joyce & Nomian Freed
Charitable Trust
100,000
(74,8461
2S.154
161.018
960,914 11,369,078)
384.220
137.074
Total of fuTrds
1.264.3S4
2.391.779 12.416.517}
1.239,616
rd?A

Docusw En¥ek)Fe10.. 3o5A85A84￿4￿l22.F6BDCl￿4E8FA
FOLUCULAR LYMPHOMA FOUNDATION
(A company Ilmited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
16. Analysls of net assets between funds
Analysis of net assets between funds - current year
Restricted Unrestr•cted
funds
funds
2025
2025
Total
funds
2025
Tangible fixed assels
Currenl assets
Creditors due within one year
9.074
1.767.508
{755.173)
9.074
2.032.793
{755.1731
265,285
Total
265.285
1.021.409
1.286.694
Analysis of net assets between funds - prior year
Restricted Unre$tr•cted
funds
funds
2024
2024
Total
funds
2024
Tangible fixed assets
Current assets
Creditors due within one ygar
7.381
7.381
1.881.274
2.018.348
1786.1131 1786,1131
137.074
Total
137.074
1,102.542
1.239,616
17.
Reconclllation of net movement In funds lo net cash flow from operallng actlvilies
2025
2024
Net incomelexpendrture for the year las per Statement of Financial
Activities)
47,078
124,738)
Adjustrnents for:
Depreciation eharges
Interest received
Ilncreaseydeerease in deblots
Increasel{decrease) in creditors
3,340
15.7761
{831.2131
(30.9401
2,015
{7,2411
{128.8281
674,250
Net cash provid•d byl(used inl operating adivities
{817,511 }
515,458
3Th.4￿ 44A

Do￿Sign Envelow 10.. 30s48&4&aAD￿4￿l22￿68DClA8Ea7A
FOLLICULAR LYMPHOMA FOUNDATION
(A company limited by guarantee)
NOTES TO ThE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
18. Analysls of cash and cash equivalents
2025
2024
Cash in hand
988.9
1.805,674
Total ￿$h and cash equivalents
988.906
1.805.674
19. Analysis of changes in net debt
At31
December
2025
January
2025 Cash flows
Cash al bank and in hand
1,805,674
{1,9371
{816.768)
1283)
988,906
12.2201
Debt due Viithin 1 year
1.803,737
1817.0511
986,686
20. Members. liability
The charitable company is limited by guarantee and has no share capital. In the event of the charitsble
Company being wound-up. the liability in respect of the guarantee is limited to £10 per member of the
charitable company during the time they are a rnember or within one year of ceasing to be a member, as
slated in the Memorandum and Articles of Association.
21. Related party transactions
The tharity is one of three affiliated organiSatK￿s - Ihe Follicular L￿phOrna Foundati(m {UKI, Follicular
Lymphoma Foundalion US, and Follicular Lymphoma Foundation Israel Ltd {a public benefit company) -
which share common founding Irusteeslmembers and. in part. common management. The charity holds
an equal mgmbership interest. alongside six other members. in Follicular Lyinphoma Foundation Israel
Ltd,. this interest carries no right to any distribution of profits or assets and is not considered to give the
charity control. The charity has representa￿ on the l￿rd of the Israeli entity.
During Ihe year, the tharity recharged £89.212 of shared costs to Follicular Lymphoma Foundation US.
recognised as other income in note S. Separalely. the Charity recognised £89,212 of staff costs incurred
by Follieular Lymphoma Foundalion US in respect of research pro9ramme activity. included as charitable
expenditure in note 7. Al the year end, £103,210 {2024= £nil) was receivable from Follicular Lymphoma
Foundation US in respect of costs paid on rts behalf.
The charity re￿iVed donations totalling £27,750 12024.. £nill from enkn.ties controtled by trustees. and
£82.75012024.. £84,000) of unrestricted donations from trustees (see note 111.
Trustee Lord Rithard Ifwfft Harrington is a director of Harvington Properties Ltd. Ouring the year, the
charity purchased seThices from them totslling £31.671 {2024: £Nil). At the year end. the balance
outstanding was £2.667.